{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:54Z","timestamp":1792783434836,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"PML Consortium (PML Consortium, Washington, DC)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12325-019-0886-2","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T06:28:41Z","timestamp":1550039321000},"page":"757-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Progressive Multifocal Leukoencephalopathy Consortium as a Model for Advancing Research and Dialogue on Rare Severe Adverse Drug Reactions"],"prefix":"10.1007","volume":"36","author":[{"given":"Ilse S.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Iverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion T.","family":"Kasaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"6","key":"886_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1756285615602832","volume":"8","author":"D Pavlovic","year":"2015","unstructured":"Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255\u201373.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"886_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.imbio.2018.01.002","volume":"223","author":"D Pavlovic","year":"2018","unstructured":"Pavlovic D, Patel MA, Patera AC, Peterson I. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology. 2018;223(6):508\u201317.","journal-title":"Immunobiology"},{"key":"886_CR3","doi-asserted-by":"publisher","unstructured":"Adang L, Berger J. Progressive multifocal leukoencephalopathy. F1000Res. 2015. \n                    https:\/\/doi.org\/10.12688\/f1000research.7071.1\n                    \n                  .","DOI":"10.12688\/f1000research.7071.1"},{"key":"886_CR4","doi-asserted-by":"publisher","first-page":"197807","DOI":"10.1155\/2013\/197807","volume":"2013","author":"EM Johnson","year":"2013","unstructured":"Johnson EM, Wortman MJ, Dagdanova AV, Lundberg PS, Daniel DC. Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol. 2013;2013:197807.","journal-title":"Clin Dev Immunol."},{"issue":"4","key":"886_CR5","doi-asserted-by":"publisher","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","volume":"10","author":"E Sundqvist","year":"2014","unstructured":"Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, et al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog. 2014;10(4):e1004084.","journal-title":"PLoS Pathog"},{"issue":"9","key":"886_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/infdis\/jiv755","volume":"213","author":"MJ Wortman","year":"2016","unstructured":"Wortman MJ, Lundberg PS, Dagdanova AV, Venkataraman P, Daniel DC, Johnson EM. Opportunistic DNA recombination with epstein-barr virus at sites of control region rearrangements mediating JC virus neurovirulence. J Infect Dis. 2016;213(9):1436\u201343.","journal-title":"J Infect Dis"},{"issue":"3","key":"886_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4172\/2168-975X.1000217","volume":"5","author":"EM Johnson","year":"2016","unstructured":"Johnson EM, Daniel DC. Significance of interviral recombination as novel mechanism for extending viral disease repertoire. Brain Disord Ther. 2016;5(3):127.","journal-title":"Brain Disord Ther"},{"issue":"1","key":"886_CR8","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","volume":"3","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, G\u00f6bel K, et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e195.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"886_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","volume":"8","author":"J Borchardt","year":"2016","unstructured":"Borchardt J, Berger JR. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler Relat Disord. 2016;8:145\u201350.","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"886_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","volume":"88","author":"N Schwab","year":"2017","unstructured":"Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88(12):1197\u2013205.","journal-title":"Neurology"},{"issue":"5","key":"886_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/1352458517728814","volume":"24","author":"N Schwab","year":"2018","unstructured":"Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, et al. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. Mult Scler. 2018;24(5):563\u201373.","journal-title":"Mult Scler"},{"issue":"3","key":"886_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","volume":"29","author":"EM Williamson","year":"2015","unstructured":"Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs. 2015;29(3):229\u201344.","journal-title":"CNS Drugs."},{"issue":"2","key":"886_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737175.2014.874289","volume":"14","author":"D Buck","year":"2014","unstructured":"Buck D, Hemmer B. Biomarkers of treatment response in multiple sclerosis. Expert Rev Neurother. 2014;14(2):165\u201372.","journal-title":"Expert Rev Neurother."},{"issue":"9","key":"886_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1212\/01.wnl.0000496643.57775.41","volume":"87","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Wiendl H. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. 2016;87(9):958\u20139.","journal-title":"Neurology."},{"issue":"5","key":"886_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/QAD.0000000000000201","volume":"28","author":"T Schneider-Hohendorf","year":"2014","unstructured":"Schneider-Hohendorf T, Philipp K, Husstedt IW, Wiendl H, Schwab N. Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. AIDS. 2014;28(5):793\u20135.","journal-title":"AIDS."},{"issue":"8","key":"886_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1177\/1352458515607651","volume":"22","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Gorlich D, Meinl I, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Schler. 2016;22(8):1048\u201360.","journal-title":"Mult Schler."},{"key":"886_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2014.00646","volume":"5","author":"EL Frost","year":"2015","unstructured":"Frost EL, Lukacher AE. The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy. Front Immunol. 2015;5:646.","journal-title":"Front Immunol."},{"key":"886_CR18","unstructured":"Liu M. E-Briefing on progressive multifocal leukoencephalopathy conference. In: Progressive multifocal leukoencephalopathy conference at the New York Academy of Sciences. 2013 Jun 19\u201320; New York City, New York (USA): New York Academy of Sciences; 2013."},{"issue":"6","key":"886_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s13365-015-0392-5","volume":"21","author":"AC Patera","year":"2015","unstructured":"Patera AC, Butler SL, Cinque P, Clifford DB, Elston R, Garcea RL, et al. 2nd international conference on progressive multifocal leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment. J Neurovirol. 2015;21(6):702\u20135.","journal-title":"J Neurovirol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-0886-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-0886-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-0886-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:07:45Z","timestamp":1581534465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-0886-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-0886-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}